Craig-Hallum Rates Fractyl Health (GUTS) buy, $4 Price Target
Craig-Hallum reaffirms its buy rating on Fractyl Health, Inc. with a $4 price target, a 400.75% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Craig-Hallum rated Fractyl Health, Inc. ($GUTS) "buy" with a $4 price target on July 1, 2026.
Since the rating, $GUTS is down 2.8% after 1 week, down 12.6% after 1 month and down 83.5% to date (from the $9.40 close on Jul 1, 2026).
GUTS
Fractyl Health, Inc.
Key Points
- Craig-Hallum reiterated its buy rating on Fractyl Health, Inc. (GUTS) with a $4 price target on July 1, 2026.
- Craig-Hallum's $4 price target implies 400.75% upside from Fractyl Health, Inc.'s ($GUTS) current $0.80 share price.
- Shares of Fractyl Health, Inc. traded near $0.80 on Wednesday, with a market cap of approximately $126 million.
- Nantahala Capital Management increased its stake in Fractyl Health by 23.2%, now holding over 13.3 million shares.
Get $GUTS trade alerts by text
We text you when insiders, Congress or big funds trade $GUTS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Fractyl Health, Inc. alert may contain errors. Disclosures
Craig-Hallum reiterated its buy rating on Fractyl Health, Inc. (NasdaqGM: GUTS) on July 1, 2026, maintaining a price target of $4. Analyst Chase Knickerbocker reaffirmed the firm's positive outlook on the biotechnology company.
Craig-Hallum vs. the S&P 500
Hypothetical returns from Craig-Hallum's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Fractyl Health
Several institutional investors have been active in Fractyl Health recently. Nantahala Capital Management increased its holdings by 2,518,079 shares, bringing its total to over 13.3 million shares valued at about $6.1 million, marking a 23.2% increase. 683 Capital Management also boosted its position by 679,615 shares to a total of approximately 6.7 million shares worth around $3.1 million, reflecting an 11.2% increase. Pale Fire Capital SE significantly grew its stake by 2,711,103 shares, ending with about 5.9 million shares valued at $2.7 million, an 84.5% rise. Vanguard Capital Management opened a new position with over 5.5 million shares valued at about $2.5 million.
Fractyl Health, Inc. Stock Up 33.1%
Shares of Fractyl Health, Inc. traded near $0.80 on Wednesday. The company has a market cap of approximately $126 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock has a beta of 2.34, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has traded between $0.38 and $2.44. The 50-day moving average is $0.76, while the 200-day moving average is $1.09. Fractyl has a robust current ratio of 4.28, indicating strong liquidity, though its debt-to-equity ratio stands at a high 284.5.
$GUTS price target
Fractyl Health, Inc. daily closes and this analyst's $4 target. Not advice.
Insider Buying and Selling at Fractyl Health, Inc.
There has been notable insider buying at Fractyl Health recently. On June 12, 2026, Ajay Royan acquired 23,000 shares at an average price of $0.85. Earlier, on June 10, multiple insiders, including Kelly Ann Barnes and William Bradley, bought shares at unspecified prices. William Bradley also purchased 68,493 shares at $0.73 each on the same day.
Analysts Set New Price Targets
On July 1, 2026, Craig-Hallum reiterated its buy rating on Fractyl Health, Inc. with a price target of $4. Previously, on June 4, 2026, HC Wainwright & Co. also reiterated a buy rating with a higher target of $8. The consensus among analysts is a buy rating, with a mean price target of $5.24 based on five analyst opinions.
About Fractyl Health, Inc.
Fractyl Health, Inc. is a biotechnology company focused on developing treatments for type 2 diabetes and obesity. Headquartered in Burlington, Massachusetts, and led by CEO Dr. Harith Rajagopalan, the company employs approximately 100 people. It is known for its Revita DMR System, an outpatient procedure aimed at modifying duodenal dysfunction, and Rejuva, a gene therapy platform for long-term remission of metabolic diseases.
Bottom Line
Craig-Hallum's reiterated buy rating highlights continued confidence in Fractyl Health's potential. The company's focus on novel treatments for diabetes and obesity makes it a key player in the biotechnology sector. Investors should note that analyst ratings are based on backward-looking data and may not reflect current market conditions.
Related Filing Alerts
Source: Craig-Hallum's rating change on $GUTS (Jul 1, 2026). Written by software, not financial advice. How we make alerts